3 results
Approved WMORecruiting
Evaluation of the effect of treatment with the Meniett in patients with unstable Menière*s disease.
Approved WMOCompleted
The purpose of this study is to evaluate the safety and effectiveness of adalimumab for the treatment of moderate to severe Crohn*s disease in children between 6-17 years of age. In addition, information will be collected to select the most…
Approved WMORecruiting
This is a Phase 3 multicenter study that includes two periods. Period 1 is designed to compare the safety, tolerability, and efficacy of upadacitinib low dose once daily (QD) and high dose B QD versus placebo and versus adalimumab every other week (…